Ichor Therapeutics has built out a high throughput screening core and has a 200,000 compound small molecule library available in house for drug discovery. Additionally, Ichor affiliate Antoxerene holds patented technology for robust production of full-length proteins (rather than fragments) for screening applications, and we have successfully expressed several high yield bioactive full-length proteins that are known to be difficult or impossible to express.
If anyone in the community has robust screens available for age-associated pathways or has an age-associated pathway of interest that could be drug-able but cannot be targeted for lack of sufficient protein for screening, please reach out to us to discuss partnering opportunities.
